Prothena is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for rare peripheral amyloid and neurodegenerative diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our diversified portfolio is designed to make a significant impact on rare peripheral amyloid.
Prothena’s success is driven by our people. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, except ourselves. Our values connect us – you will see and feel them come to life in all we do – together.
At Prothena, our culture reflects our values which are brought to life every day by the following characteristics:
Selfless
Patients come first and we’re in this together. Our environment is collaborative and we measure success through our collective accomplishments.
Courageous
Transformational innovation leads to novel treatments. “Tried-and-true” won’t produce breakthroughs for patients – a pioneering spirit, willingness to accept risk and try new approaches will. Each individual and team is expected to bring their heart, experience and trust on our journey.
Imaginative
We value and encourage a creative approach across all aspects of our work. We challenge ourselves and each other to think beyond what is known and approach our work through a lens of continuous improvement.
Joyful
Humor and heart allow us to tackle the seriousness of our work. Excellence and fun are not at odds – we love what we do and enjoy the journey.
For more information, please visit our website at http://www.prothena.com and follow us on Twitter @ProthenaCorp.
Prothena’s success is driven by our people. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, except ourselves. Our values connect us – you will see and feel them come to life in all we do – together.
At Prothena, our culture reflects our values which are brought to life every day by the following characteristics:
Selfless
Patients come first and we’re in this together. Our environment is collaborative and we measure success through our collective accomplishments.
Courageous
Transformational innovation leads to novel treatments. “Tried-and-true” won’t produce breakthroughs for patients – a pioneering spirit, willingness to accept risk and try new approaches will. Each individual and team is expected to bring their heart, experience and trust on our journey.
Imaginative
We value and encourage a creative approach across all aspects of our work. We challenge ourselves and each other to think beyond what is known and approach our work through a lens of continuous improvement.
Joyful
Humor and heart allow us to tackle the seriousness of our work. Excellence and fun are not at odds – we love what we do and enjoy the journey.
For more information, please visit our website at http://www.prothena.com and follow us on Twitter @ProthenaCorp.
Location: Ireland
Employees: 51-200
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnova.... |
Mentions in press and media 13
| Date | Title | Description |
| 09.03.2026 | Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyop... | Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial... |
| 27.02.2026 | Prothena Announces up to $100 Million Share Repurchase Plan | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized ... |
| 23.02.2026 | Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and... |
| 12.02.2026 | Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and ... |
| 12.12.2025 | Prothena Announces Board of Directors Update | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothen... |
| 06.11.2025 | Prothena Reports Third Quarter 2025 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and ... |
| 25.03.2024 | Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior | Novo Nordisk is adding on to its cardiovascular drug pipeline with the acquisition of Cardior Pharmaceuticals, a genetic medicines developer whose lead program is in mid-stage clinical testing in heart failure. The Danish pharmaceutical gia... |
| 20.02.2024 | Health | Inside the plan to diagnose Alzheimer’s in people with no memory problems — and who stands to benefit | Melody Petersen | Los Angeles Times (TNS) In a darkened Amsterdam conference hall this summer, a panel of industry and academic scientists took the stage to announce a plan to radically expand the definition of Alzheimer’s disease to includ... |
| 26.07.2021 | Poster: Development of a Dual Aβ-Tau Vaccine for the Prevention of Alzheimer Disease | 52980 Development of a Dual Aβ-Tau Vaccine for the Prevention of Alzheimer Disease Robin Barbour, Abderrahman Elmaarouf, Andriani Ioannou, LeeAnn Louie, Heather Prill, Michael Skov, Stephen Tam, Clara Tourino, Brian Campbell, Gene G. Kinney... |
| 11.05.2021 | PROTHENA CORPORATION PLC PROTHENA : ANNOUNCES ACHIEVEMENT OF $60 MILLION MILESTONE FROM ROCHE FOR FIRST PATIENT DOSED IN PHASE 2B STUDY OF PRASINEZUMAB IN EARLY PARKINSON'S DISEASE | DUBLIN, Ireland - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced that the Company has earned a $60 milli... |
Show more